Ameritox applauds President Trump’s declaration of opioid crisis as national public health emergency

NewsGuard 100/100 Score

Ameritox, a national leader in medication monitoring solutions for patients prescribed opioids and other medications for chronic pain and severe mental illness, today applauded the declaration of the opioid crisis as a national public health emergency by President Donald J. Trump. Ameritox has long advocated for dedication of additional attention and resources toward the opioid epidemic - the largest man-made epidemic in history.

"The patients Ameritox serves are not often connected to the opioid epidemic, in part because their clinicians utilize medication monitoring to help identify if a patient is headed down a dangerous path," said Todd Gardner, Chief Executive Officer of Ameritox. "This declaration will help equip all who are fighting the opioid epidemic with the additional tools they need to claim control - medication monitoring can and should be one of those tools," Gardner said. "Appropriate prescribing with monitoring and intervention can help stop the epidemic, and will improve clinical outcomes and lower costs."

Ameritox and Gardner recently sent a letter to the Chairman and Vice-Chairman of the United States House of Representatives Committee on Energy and Commerce in support of Jessie's Law, legislation aimed at spurring important conversations about opioid addiction among clinicians and patients, which was passed by the U.S. Senate and awaits action in the House.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative malaria prodrug targets liver, enhances efficacy while reducing toxicity, preclinical studies show